Pharmaceutical News

RSS

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

In a major international trial, researchers from McMaster University in Canada, found that the hypertension drug irbesartan reduced the risk of heart failure complications and the combination of stroke, other embolic events and transient ischemic events, also known as ministrokes, in patients with atrial fibrillation.

2 Sep 2009

NF-kappa B inhibitors protect against toxicity during radiation treatment

Directly inhibiting the activity of a key protein mediator of inflammation reduced radiation toxicity in zebrafish embryos, and may ultimately be of help to patients receiving radiation therapy, according to researchers from the Kimmel Cancer Center at Jefferson.

2 Sep 2009

Schering-Plough launches CLARITIN 12-Hour for non-drowsy relief from allergy symptoms

Schering-Plough Corporation (NYSE: SGP) today announced the introduction of CLARITIN 12-Hour, the only 12-hour allergy medicine found in the allergy aisle. New CLARITIN 12-Hour lasts all day and provides effective, non-drowsy relief from the worst indoor and outdoor allergy symptoms. The product is available for adults and children ages six and up.

1 Sep 2009

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Medivir (STO:MVIRB) has deepened its presence, and expanded its commercial interest, in the therapeutic area of bone diseases by selecting a further candidate drug that targets the protease cathepsin K, a recognized drug target in this area. This builds on Medivir’s existing interest in bone related disorders which includes already one candidate drug and positive phase I experience from MIV-701.

1 Sep 2009

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Bio-Matrix Scientific Group, Inc. Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property.

1 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009

Cumberland Pharmaceuticals to discuss its recently approved FDA product at the UBS Conference

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that Chief Executive Officer A.J. Kazimi will present at the UBS Global Life Sciences Conference in New York at 11:00 a.m. Eastern Time on Monday, September 21, 2009. Mr. Kazimi will provide an update on the Company and its Caldolor product, which Cumberland is preparing to launch following its recent approval by the Food and Drug Administration.

1 Sep 2009

Chemists design polymer-coated nanorods for drug manufacturers

Nanoparticles combining platinum and gold act as superefficient catalysts, but chemists have struggled to create them in an industrially useful form. Rice University chemists have answered the call this week with a polymer-coated version of gold-platinum nanorods, the first catalysts of their kind that can be used in the organic solvents favored by chemical and drug manufacturers.

1 Sep 2009

BioSyent's subsidiary BioSyent Pharma signs an exclusive product development agreement

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) announces that its subsidiary BioSyent Pharma Inc. has signed an exclusive product development, supply and distribution agreement with a new partner for a new product under its Hospital Products Division.

1 Sep 2009

FDA approves Hospira's six new vial presentations of heparin

Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's applications for six new presentations of therapeutic heparin in single- and multiple-dose vials.

1 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

MRRI research study to investigate how zolpidem might restore consciousness for patients in the vegetative state

Moss Rehabilitation Research Institute (MRRI), the research arm of MossRehab, one of the world’s leading clinical rehabilitation centers, has launched an ambitious research study to investigate how the sleep drug zolpidem might restore consciousness for patients in the vegetative state.

31 Aug 2009

Walgreens to provide flue shots faster and easier this season

Walgreens (NYSE:WAG)(NASDAQ:WAG) is making it faster and easier to get a flu shot this season. The nation’s largest drugstore chain today announced it will begin offering seasonal flu shots on Sept. 1 at more than 7,000 points of care nationwide, including nearly all of its stores in 50 states and almost 350 in-store Take Care Clinics.

31 Aug 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

Takeda visits managed care professionals to promote its two new drugs

According to SDI, a leading healthcare market insight and analytics firm, in spring 2009, Takeda made more visits to managed care professionals than any other pharmaceutical manufacturer, accounting for almost 7% of contacts recorded in SDI’s Managed Care Pharmacy Executive and Managed Care Medical Director audits.

31 Aug 2009

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Peregrine Pharmaceuticals, Inc., today announced that noted cancer researcher Bruce Chabner, M.D., will serve as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program.

31 Aug 2009

Tianyin Pharmaceutical to discuss its diversified product portfolio at the Rodman & Renshaw Annual Global Investment Conference

Tianyin Pharmaceutical Co. Inc., a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference, to be held September 9-11, 2009, at the New York Palace Hotel in New York City.

31 Aug 2009

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

POZEN Inc. (NASDAQ:POZN), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for VIMOVO™ (enteric-coated naproxen / immediate release esomeprazole magnesium, formerly know as PN 400).

31 Aug 2009

Doxorubicin granted orphan drug designation by the FDA

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that the U.S. Food & Drug Administration granted Delcath's request for orphan drug designation for doxorubicin for the treatment of hepatocellular carcinoma (HCC), also known as primary liver cancer. Clinicians in the U.S. diagnose nearly 20,000 cases of HCC annually.

31 Aug 2009

IntelGenx Technologies shareholder conference call to update shareholders on CPI-300

Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. ("IntelGenx") will be holding a shareholder conference call to update shareholders on the company's CPI-300 product and remark on related legal proceedings. The call will be held on Tuesday September 1, 2009 at 2.30 p.m. Eastern Standard Time.

31 Aug 2009

Pharmaceutical News

Irbesartan drug minimizes heart failure complications in patients with atrial fibrillation

NF-kappa B inhibitors protect against toxicity during radiation treatment

Schering-Plough launches CLARITIN 12-Hour for non-drowsy relief from allergy symptoms

Medivir adds MIV-711 to bone-related disorder treatment candidate portfolio

Bio-Matrix Scientific Group's new opportunities in cancer treatment and intellectual property discussed

Cimzia approved for treating adult patients with rheumatoid arthritis

Cumberland Pharmaceuticals to discuss its recently approved FDA product at the UBS Conference

Chemists design polymer-coated nanorods for drug manufacturers

BioSyent's subsidiary BioSyent Pharma signs an exclusive product development agreement

FDA approves Hospira's six new vial presentations of heparin

OHSU study reveals that fluoroquinolones may cause double vision

MRRI research study to investigate how zolpidem might restore consciousness for patients in the vegetative state

Walgreens to provide flue shots faster and easier this season

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Takeda visits managed care professionals to promote its two new drugs

Cancer researcher to serve as Peregrine Pharmaceuticals' clinical advisor for bavituximab cancer program

Tianyin Pharmaceutical to discuss its diversified product portfolio at the Rodman & Renshaw Annual Global Investment Conference

New Drug Application for VIMOVO accepted by U.S. Food and Drug Administration

Doxorubicin granted orphan drug designation by the FDA

IntelGenx Technologies shareholder conference call to update shareholders on CPI-300

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News